All Episodes
Displaying 201 - 220 of 381 in total
MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for ALL, and BAX variants and resistance to BH3-mimetics in AML
In this week's episode, we’ll discuss the dynamics of measurable residual disease, or MRD, over time in myeloma patients undergoing ixazomib maintenance. Serial measur...
Itacitinib monotherapy for GVHD, the role of ERG in EVI1-driven AML, and germline DDX41 mutations in myeloid neoplasms
In this week's episode, we’ll discuss the safety and efficacy of itacitinib monotherapy in low-risk acute GVHD, learn how ERG was discovered to be a key transcriptiona...
Stem cell transplant for SCD normalizes brain blood flow, novel GALE variants disrupt platelet development, and revisiting risk classification in NPM1-mutant AML
In this week’s episode, new research shows that in children with sickle cell disease, stem cell transplantation normalizes blood flow in the brain. The improvements in...
Review Series on Single-Cell Genomics
In this bonus episode Associate Editor, Dr. Bertie Göttgens and Dr. Ravi Majeti discuss the series on Single Cell Genomics and Heme Malignancies-Leukemia/MPNs. Blood...
Allogeneic transplantation in older and infirm AML patients, cilta-cel in progressive multiple myeloma, and anti-CD20 therapy in relapsed TTP
In this week’s episode we’ll discuss the benefits of allogeneic hematopoietic stem cell transplantation in older and medically infirm patients with AML, learn more abo...
Piezo antigens define a new blood group system, enasidenib in mutant-IDH2 relapsed/refractory AML, and breakthrough COVID-19 despite prophylaxis in B-cell malignancies
In this week’s episode, we’ll discuss new research revealing that the mechanosensory ion channel Piezo1 is the elusive carrier molecule of the Er blood group antigens,...
Immune thrombocytopenia in pregnancy, ASCT in adults with inborn errors of immunity, and long-term health outcomes of childhood AML survivors
In this week’s episode we’ll discuss whether pregnancy increases the risk of bleeding in women with immune thrombocytopenia, compare the outcomes of allogeneic stem ce...
How I Treat Series: Management of High-risk Patients Following Allogeneic Transplant
In this episode, Associate Editor, Dr. Robert Zeiser and Dr. Yi-Bin Chen discuss the series on How I Manage High-Risk Patients Following Allogeneic Hematopoietic Cell ...
IL-13/IL-4 signaling and fibrotic progression in myelofibrosis, VWF-targeted thrombolysis in acute ischemic stroke, and NK cell dysfunction in relapsed AML
In this week’s episode, we'll discuss involvement of IL-13 and IL-4 signaling in fibrotic progression of myelofibrosis; next, we review results on a novel agent using ...
Effects of iron repletion on donor RBC quality, long-term outcomes in relapsed/refractory hairy cell leukemia after vemurafenib, and off-the-shelf cryopreserved platelets for detecting HIT
In this week’s episode, we’ll discuss the effects of iron repletion on the quality of donated red blood cells and donor well-being, learn more about the long-term outc...
Germline predisposition variants occur in all age groups in MDS, αβ-haplo-HCT excels in children with acute leukemias/MDS, and poor outcomes after CAR T cell failure in B-cell lymphomas
In this week’s episode, research shows that in patients with myelodysplastic syndromes, or MDS, the frequency of pathogenic or likely pathogenic germline variants is r...
Predicting VTE in multiple myeloma, azithromycin promotes relapse after HSCT, and dual antigen targeted NK cells in B cell malignancies
In this week’s episode we’ll discuss the newly developed PRISM score for risk prediction of venous thromboembolism in multiple myeloma, learn more about relapse-promot...
Using MRD to guide CLL treatment intensity, donor NK cells boost immune reconstitution after haplo-BMT, and EZH2 drives retinoic acid resistance in variant APL
In this week’s episode we discuss encouraging results of a phase 2 study using a sequential ibrutinib-venetoclax treatment approach driven by MRD findings in individua...
Tolerability of CD19 CAR T cells in lymphoma, causes of platelet spherocytosis, and using prebiotics to reduce GVHD
In this week’s episode, we’ll discuss patient-reported outcomes in the phase 3 ZUMA-7 trial of CAR T-cell therapy in second-line relapsed/refractory large B-cell lymph...
Transplant in adult Ph+ ALL, acalabrutinib and ventricular arrythmias, and antibody prevention of fetal/neonatal alloimmune thrombocytopenia
In this week’s episode we discuss the role of allogeneic transplant in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. In a retrospe...
Restricting dietary methionine in AML, transferrin in high altitude-induced hypercoagulability, and LIF as protection against GVHD
In this week’s episode, we’ll learn more about the impact of dietary methionine restriction on the progression of AML, discuss transferrin upregulation as a cause of h...
Sickle hemoglobin activates monocytes via TLR4, germinal center B cells provide a niche for T-cell lymphoma, and a combination immunosuppression regimen for acquired hemophilia A
In this week’s episode, we will review a study that cell-free hemoglobin S was found to induce high levels of pro-inflammatory cytokine production in monocytes. The ef...
Lineage switching in MLL/AF4 leukemia, ibrutinib in mantle cell lymphoma with CNS relapse, and gilteritinib plus azacitidine in newly diagnosed FLT3-mutated AML
In this week’s episode we’ll discuss the role of epigenetic regulator genes in lineage switching in MLL/AF4 leukemia, learn more about the efficacy of ibrutinib in man...
Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL
In this week’s episode we will review data showing that lenalidomide promotes development of TP53-mutated, therapy-related myeloid neoplasms. Next, we'll discuss the f...
Review Series on Megakaryopoiesis and Platelet Production
Megakaryocytes contribute to multiple processes in the body, including platelet production and regulation of hematopoietic stem cells. Therefore, it is not surprising ...
